MOLECULAR INFORMATION
Molecular information
- Length
- 11 amino acids
- Type
- 11-AA EPO-derived peptide · innate-repair receptor agonist · non-erythropoietic
Amino acid sequence
Pyr-Glu-Gln-Leu-Glu-Arg-Ala-Leu-Asn-Ser-Ser ARA-290 (cibinetide) is an 11-amino-acid synthetic peptide derived from the helix B sequence of erythropoietin (EPO). Unlike full-length EPO it does not stimulate erythrocytosis; instead it signals through the innate-repair receptor to suppress inflammatory injury. Developed by Araim Pharmaceuticals.
Status
- Phase 2 in sarcoidosis-associated small-fibre neuropathy
- Phase 2 in painful diabetic neuropathy
- No regulatory authorisation
Why we grade it C
Multiple completed Phase 2 trials with consistent signal on neuropathy endpoints. Mechanism is novel and non-redundant with existing analgesics. Promotion above C requires Phase 3; no active sponsor has progressed the molecule into a pivotal programme as of writing.